Previous Article | Next Article ![]()
Infection and Immunity, January 2003, p. 557-561, Vol. 71, No. 1
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.1.557-561.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Mauro Cortez, and Nobuko Yoshida*
Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Received 24 June 2002/ Returned for modification 26 August 2002/ Accepted 10 October 2002
|
|
|---|
|
|
|---|
Metacyclic trypomastigotes can invade and replicate in the gastric mucosal epithelium, and it appears that gastric mucosal invasion is the unique portal of entry for systemic T. cruzi infection after oral challenge (7). It has been shown that insect-derived metacyclic trypomastigotes delivered orally were sufficient for consistent infection of 100% of BALB/c mice, whereas blood form trypomastigotes were found to initiate mucosal infection rarely, suggesting that metacyclic forms have uniquely specialized functions for mucosal invasion (6). They may be resistant to proteolytic enzymes present in mucosal secretion, and the possibility has been raised that metacyclic forms express stage-specific surface molecules not present on blood trypomastigotes, which are required for adhesion to mucosal epithelial surface receptors or for the penetration of mucin, the protective secreted coat that lines mucosal surfaces (6).
A metacyclic-stage-specific surface molecule that could be involved in invasion of epithelial cells of the gastric mucosa is gp82. This glycoprotein, identified by MAb 3F6 in metacyclic trypomastigotes but not in blood trypomastigotes, epimastigotes, or amastigotes (18), has been implicated in T. cruzi penetration of cultured mammalian cells (10). gp82 is an adhesion molecule that binds to epithelial cells in a receptor-mediated manner and induces Ca2+ mobilization (11), which is an essential requirement for T. cruzi entry into host cells (5, 9, 17). In addition to the role of gp82 in mucosal infection upon oral challenge, it remains to be determined whether gp82 adheres to gastric mucin and to what extent the action of proteolytic enzymes digests gp82 and affects the infectivity of metacyclic forms. To address these questions, in this study, we performed in vivo and in vitro experiments with T. cruzi metacyclic trypomastigotes obtained in axenic cultures.
T. cruzi isolate CL, from the insect Triatoma infestans (2), was used. Parasites were maintained alternately in mice and in liver infusion tryptose medium. Grace's medium was used to obtain cultures enriched in metacyclic trypomastigotes, which were purified by passage through a DEAE-cellulose column as previously described (18). For oral infection, metacyclic forms were introduced by the intrapharyngeal route into 4- to 6-week-old female BALB/c mice through a plastic tube adapted to a 1-ml plastic syringe. Parasitemia was monitored by examining 5-µl peripheral blood samples under a phase-contrast microscope. HeLa cells, human carcinoma-derived epithelial cells, were grown at 37°C in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum, streptomycin (100 µg/ml), and penicillin (100 U/ml) in a humidified 5% CO2 atmosphere. Mammalian cell invasion assays were performed essentially as previously described (19), at a parasite-to-HeLa cell ratio of 10:1. Native gp82 was purified by antibody affinity Sepharose column chromatography from detergent-solubilized extracts of metacyclic trypomastigotes (20). Recombinant proteins J18, comprising the full-length gp82 sequence in frame with glutathione S-transferase, and J18b, which encodes 293 amino acids of the C-terminal domain, were generated in Escherichia coli and purified as previously detailed (12, 13). The purity of the isolated protein was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and staining with Coomassie blue, and its specificity was assessed by immunoblotting with MAb 3F6. An assay of gp82 binding to mucin from porcine stomach (type III; Sigma) was performed as follows. Microtiter plates (96 wells) coated with gastric mucin in phosphate-buffered saline (PBS; 10 µg/well) were blocked with PBS containing 10% fetal calf serum for 1 h at room temperature and then incubated sequentially, at 37°C for 1 h, with native or recombinant gp82, with MAb 3F6 (18) or polyclonal monospecific antibody to recombinant gp82 (13), and with peroxidase-conjugated anti-mouse IgG, in PBS containing 10% fetal calf serum. The final reaction was revealed by o-phenylenediamine as previously described (10). Binding of recombinant gp82 to HeLa cells was assayed by enzyme-linked immunosorbent assay (ELISA) as detailed elsewhere (10). For treatment with the proteolytic enzymes pepsin (Sigma) and proteinase K (Life Technologies), parasites were incubated at 37°C for 30 min with the enzymes, washed three times in PBS, and then used for experiments. Immunoblotting of parasite extracts was done as detailed elsewhere (19), and the final reaction was revealed by diaminobenzidine plus H2O2. To determine the levels of T. cruzi surface molecules that react with MAb 3F6, live parasites (3 x 107 cells) were incubated for 1 h on ice with MAb 3F6 or with unrelated isotype-matched MAb 1C3 directed to Leishmania amazonensis gp63 (1) and then processed for flow cytometry as previously described (11).
In preliminary experiments, we ascertained that oral administration of culture-derived T. cruzi metacyclic trypomastigotes to BALB/c mice leads to systemic infection. Next, we examined whether the metacyclic-stage surface molecule gp82 is implicated in mucosal infection. The parasites were preincubated with gp82-specific MAb 3F6 or with unrelated isotype-matched MAb 1C3 and then inoculated by the intrapharyngeal route into BALB/c mice. As the source of antibody, we used ascitic fluid, which was mixed with the parasite suspension (vol/vol) in a volume of 100 µl. After 30 min of incubation at room temperature, 1.2 ml of PBS was added and 0.2 ml of a parasite suspension containing 4 x 105 metacyclic forms was given to each mouse. Starting on day 13 postinoculation, blood samples were examined twice a week for the presence of parasites. As shown in Fig. 1, the parasitemia levels of mice that received metacyclic forms pretreated with MAb 3F6 were greatly reduced compared to those of the control group. At the peak of parasitemia, control animals suffered from cachexia and one died at day 25 postinfection. The experiment was repeated and gave similar results, confirming the infection-blocking activity of MAb 3F6. We presume that this antibody, which is devoid of any parasite-agglutinating or -immobilizing effect, acts by blocking gp82-mediated mucosal cell invasion, provided that the host cell binding site of gp82 is contiguous to and overlaps the epitope for MAb 3F6 (8). In addition, experiments were done to examine the effect of anti-T. cruzi MAbs other than MAb 3F6 by preincubating metacyclic trypomastigotes with MAb 1G7, which is directed to metacyclic-stage-specific surface glycoprotein gp90 (18), or with MAb 3C9, which recognizes a sialic acid-containing epitope in trypomastigote glycoproteins (14), before oral administration. We found no inhibitory effect of MAb 1G7 or MAb 3C9 on T. cruzi infection: both the control and experimental animals developed high parasitemias, and
20% mortality was observed in all groups.
![]() View larger version (18K): [in a new window] |
FIG. 1. Inhibitory effect of MAb 3F6 on oral T. cruzi infection by metacyclic trypomastigotes. Parasites pretreated with MAb 3F6 were given orally to a group of five BALB/c mice. The control group received parasites treated with unrelated MAb 1C3. Each datum point corresponds to the mean parasitemia of five animals in each group of mice.
|
![]() View larger version (16K): [in a new window] |
FIG. 2. Binding of T. cruzi metacyclic-stage surface molecule gp82 to gastric mucin. (A) gp82, either purified from parasite extracts or as a recombinant protein containing the entire gp82 peptide sequence (J18) or the C-terminal domain of gp82 (J18b), at 10 µg/ml, was added to microtiter plates coated with porcine gastric mucin. (B) Increasing concentrations of the T. cruzi surface molecule gp90, gp35/50, or gp82, as well as the recombinant protein J18, were added to wells in microtiter plates coated with gastric mucin. (C) Increasing doses of J18b were added to plates containing adherent HeLa cells. In all ELISAs, after washes, the plates were sequentially incubated with anti-gp82 antibody, anti-gp90 MAb 1G7, or anti-gp35/50 MAb 10D8 and anti-mouse immunoglobulin conjugated to peroxidase. The bound enzyme was revealed by using o-phenylenediamine. The values are the means ± standard deviations of triplicate samples. O.D.492, optical density at 492 nm.
|
To successfully invade the mucosal epithelium, metacyclic trypomastigotes should resist the acidic pH within the host stomach and digestion by the proteolytic enzyme pepsin. To test their resistance to acidic conditions, we incubated parasites at different pHs lower than 7.0. At pH 3.5, in citrate buffer, metacyclic forms remained fully motile and morphologically indistinguishable from parasites at pH 7.0. When the pH was lowered to 3.0, some of the parasites lost motility. We examined their susceptibility to pepsin by treating parasites for 30 min at 37°C with 2 mg of pepsin per ml (optimal activity at pH 2.0 to 4.0) in citrate buffer at pH 3.5. After washings in PBS, the parasites were used for cell invasion assays and analysis by SDS-PAGE and immunoblotting. Pepsin-treated parasites showed the same protein profile as the untreated control and preserved intact the gp82 molecule (Fig. 3A), as well as the ability to enter HeLa cells (data not shown). Bovine serum albumin treated with pepsin at pH 3.5 was completely digested, showing that the enzyme was fully active. In addition to pepsin, we also tested the effects of other proteolytic enzymes, such as trypsin, papain, and proteinase K. The results obtained with trypsin and papain were similar to those obtained with pepsin. However, when metacyclic forms were treated with 1 mg of proteinase K per ml (optimal activity at pH 6.5 to 9.5) at pH 7.0 for 30 min at 37°C, we observed extensive protein digestion and conversion of gp82 to a smaller molecule (
35 kDa) that was still recognized by MAb 3F6 (Fig. 3A). By analyzing the parasites by flow cytometry, we found that the levels of MAb 3F6-reactive surface molecules were comparable in proteinase K-treated and untreated samples (Fig. 3B). Recognition by MAb 3F6 upon proteinase K treatment indicated that the gp82 host cell binding site, which is located contiguous to and downstream of the epitope for MAb 3F6 (positions 244 to 263), was preserved and implied that the enzymatic treatment would not affect parasite infectivity. Accordingly, proteinase K-treated metacyclic trypomastigotes invaded HeLa cells at the same rate as untreated controls (Fig. 3C).
![]() View larger version (39K): [in a new window] |
FIG. 3. Effects of proteolytic enzymes on T. cruzi metacyclic-stage trypomastigotes. (A) Parasites, untreated or treated with pepsin or proteinase K, were analyzed by SDS-PAGE, staining with Coomassie blue, and immunoblotting with MAb 3F6. Note the pepsin digestion of bovine serum albumin, but not of metacyclic-form proteins, including gp82, which were susceptible to proteinase K digestion. (B) Live parasites, untreated (-) or treated with proteinase K (+), were reacted with MAb 3F6, fixed, and then analyzed by flow cytometry. (C) Control and proteinase K-treated metacyclic forms were used for HeLa cell invasion assay. Values represent the means ± standard deviation of three experiments.
|
We thank Daniele Ferreira for help with assays of gp82 binding to gastric mucin and Sergio Schenkman for reading the manuscript and for suggestions.
Present address: Universidade de São Paulo, Instituto de Ciências Biomédicas, Departamento de Farmacologia, São Paulo, SP, Brazil. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»